MENU
WDNA
ETF ticker: BATS
PRICE
CHANGE
NET ASSETS

WDNA stock forecast, quote, news & analysis

The investment seeks to track the price and yield performance, before fees and expenses, of the WisdomTree BioRevolution Index (“index”)... Show more

Category: #Health
WDNA
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for WDNA with price predictions
Aug 13, 2026

WDNA's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for WDNA turned positive on August 07, 2026. Looking at past instances where WDNA's MACD turned positive, the stock continued to rise in of 40 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 04, 2026. You may want to consider a long position or call options on WDNA as a result. In of 73 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where WDNA advanced for three days, in of 269 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 241 cases where WDNA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

WDNA broke above its upper Bollinger Band on August 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), AstraZeneca PLC (NYSE:AZN), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Regeneron Pharmaceuticals (NASDAQ:REGN), Archer Daniels Midland Company (NYSE:ADM).

Industry description

The investment seeks to track the price and yield performance, before fees and expenses, of the WisdomTree BioRevolution Index (“index”). The fund generally uses a representative sampling strategy to achieve its investment objective, meaning it generally will invest in a sample of the securities in the index whose risk, return and other characteristics resemble the risk, return and other characteristics of the index as a whole. The index is designed to provide exposure to equity securities of exchange listed companies globally that will be significantly transformed by advancements in genetics and biotechnology. The fund is non-diversified.

Market Cap

The average market capitalization across the WisdomTree BioRevolution ETF ETF is 54B. The market cap for tickers in the group ranges from 64.65K to 1.08T. LLY holds the highest valuation in this group at 1.08T. The lowest valued company is BAYN at 64.65K.

High and low price notable news

The average weekly price growth across all stocks in the WisdomTree BioRevolution ETF ETF was 5%. For the same ETF, the average monthly price growth was 5%, and the average quarterly price growth was 20%. ARCT experienced the highest price growth at 29%, while BYND experienced the biggest fall at -23%.

Volume

The average weekly volume growth across all stocks in the WisdomTree BioRevolution ETF ETF was -29%. For the same stocks of the ETF, the average monthly volume growth was 7% and the average quarterly volume growth was -16%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 51
P/E Growth Rating: 62
Price Growth Rating: 43
SMR Rating: 80
Profit Risk Rating: 82
Seasonality Score: -10 (-100 ... +100)
View a ticker or compare two or three
WDNA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Details
Category
Health
Address
WisdomTree Trust380 Madison AveNew York
Phone
866-909-9473
Web
www.wisdomtree.com
WDNA's MACD Histogram crosses above signal line